Therefore, these results strongly argue for a therapeutic strategy in which the simultaneous inhibition of the epigenetic complex G9a/DNMT1/UHRF1 could be leveraged to prime the PDAC tumor and its microenvironment for a better response to immune therapies. The gene discussed is EHMT2; the disease is neoplasm.